Acerus Pharmaceuticals Corp. | |
Stock Exchange | Other OTC |
EPS |
$0.07 |
Market Cap |
$42.96 M |
Shares Outstanding |
213.19 M |
Public Float |
- |
Acerus Pharmaceuticals Corp. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
235.24 M |
Public Float |
- |
Acerus Pharmaceuticals Corp. | |
Stock Exchange | Toronto Stock Exchange Prices |
EPS |
CAD0.11 |
Market Cap |
CAD27.43 M |
Shares Outstanding |
213.12 M |
Public Float |
97.53 M |
Address |
2486 Dunwin Drive Mississauga Ontario L5L 1J9 Canada |
Employees | - |
Website | http://www.aceruspharma.com |
Updated | 07/08/2019 |
Acerus Pharmaceuticals Corp. operates as a pharmaceutical company, which engages in the development, manufacture, production, marketing and distribution of women and men's health products. It focuses on the treatment of urology, hormone replacement therapy, and female dysfunction. Its products include Estrace, Natesto, and Tefina. |